Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02325401 · ClinicalTrials.gov registry record · Phase 1
Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
A Phase 1 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02325401 is a Phase 1 study that has completed, run by University of Cincinnati. The registered enrollment target is 20 participants.
The verdict
NCT02325401, a Phase 1 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the safety of adding metformin to standard of care. The standard of care treatment will be cisplatin once every 3 weeks for 3 treatments and radiation for 7 weeks. Metformin is a medication that is currently used to treat diabetes. Increasing amounts of metformin will be given to groups of patients already receiving normal treatment for their cancer to see if metformin causes any good effects by killing your cancer or bad effects (side effects).
Interventions
- DRUG Cisplatin
- RADIATION Radiation Therapy
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-05-11 |
| Est. Completion | 2020-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02325401
The ClinicalTrials.gov registry entry for NCT02325401 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT02325401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02325401 about?
NCT02325401 is a clinical study titled "Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma". The purpose of this research study is to test the safety of adding metformin to standard of care. The standard of care treatment will be cisplatin once every 3 weeks for 3 treatments and radiation for 7 weeks. Metformin is a medication that is currently used to treat diabetes. Increasing amounts of...
What is the current status of trial NCT02325401?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2015-05-11. Estimated completion is 2020-02-21.
What interventions are being tested in trial NCT02325401?
The interventions under investigation include: Cisplatin (DRUG), Radiation Therapy (RADIATION), Metformin (DRUG).
Who is sponsoring clinical trial NCT02325401?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.